Otsuka's kidney disease drug shows over 50% reduction in protein in urine
06/06/2025 11:09
June 6 (Reuters) - Otsuka's 4578.T drug for a type of kidney disease showed over 50% reduction in protein in patient's urine in a late-stage trial, the Japan-based company said on Friday. (Reporting by Sriparna Roy in Bengaluru) ((Sriparna.Roy@thomsonreuters.com;))
Recent news on Otsuka Holdings
See all newsOtsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Brief: Otsuka Pharmaceutical Announces Ulefnersen Early Access Program For Eligible People Living With FUS-ALS
Brief: Otsuka Pharmaceutical Says Phase 3 Fusion Results For Ulefnersen Met Primary Endpoint
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit In Rezilient3 Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Climb Bio rises after early-stage data for kidney disease drug